A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

@article{Fehniger2011AP2,
  title={A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.},
  author={Todd A Fehniger and G L Uy and Kathryn Trinkaus and Alissa D Nelson and Jeffery A Demland and Camille N. Abboud and Amanda Cashen and K Stockerl-Goldstein and Peter Westervelt and John F. DiPersio and Ravi Vij},
  journal={Blood},
  year={2011},
  volume={117 6},
  pages={1828-33}
}
Older patients with acute myeloid leukemia (AML) have limited treatment options and a poor prognosis, thereby warranting novel therapeutic strategies. We evaluated the efficacy of lenalidomide as front-line therapy for older AML patients. In this phase 2 study, patients 60 years of age or older with untreated AML received high-dose (HD) lenalidomide at 50 mg daily for up to 2 28-day cycles. If patients achieved a complete remission (CR)/CR with incomplete blood count recovery (CRi) or did not… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Recent developments in management of older patients with acute myeloid leukemia.

Therapeutic advances in hematology • 2012
View 2 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Phase I study of lenalidomide in acute leukemia: remissions in post-allogeneic relapse of acute myeloid leukemia

JC Chandler, RB Klisovic, MA Phelps
Blood • 2010

and Drug Administration

U. S. Foo
Lenalidomide package insert. http://www.accessdata.fda.gov/ drugsatfda_docs/label/2006/021880s001.pdf. Accessed May 19, • 2010

Similar Papers

Loading similar papers…